title: Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy.
abstract: OBJECTIVE
  To identify whether veterans receiving androgen-deprivation therapy (ADT) are screened at any time by bone mass measurement.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Veterans Administration Tennessee Valley Healthcare System (VA-TVHS).
  
  
  METHODS
  All male veterans who received at least one dose of goserelin or leuprolide within the fiscal years October 1, 2005, through September 30, 2009.
  
  
  METHODS
  Data from patients' charts were extracted for demographic information (race, age, and weight prior to the initial injection); date of initiation of therapy; the use of calcium, vitamin D, bisphosphonate, or calcitonin therapy; and documented bone-mineral density testing.
  
  
  METHODS
  To determine whether veterans receiving ADT with goserelin or leuprolide for prostate cancer were screened at any time for BMD more or less than rates as documented in previous literature.
  
  
  RESULTS
  22.8% of veterans were screened for BMD, which was statistically significant when compared with results found in previous literature.
  
  
  CONCLUSIONS
  Although rates of BMD testing were higher at VA-TVHS compared with previous literature, this rate is still low given the well-known risk of accelerated osteoporosis associated with ADT.
authors.affiliation: Veterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee.
authors.forename: Valerie
authors.initials: V
authors.lastname: D'Alesio
authors.forename: Brent E
authors.initials: BE
authors.lastname: Salvig
authors.forename: T Neal
authors.initials: TN
authors.lastname: Fourakre
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000728:Androgens / Q000172:deficiency*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D003430:Cross-Sectional Studies; D017273:Goserelin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy; D018570:Risk Assessment; D014728:Veterans
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D016729:Leuprolide